Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Bispecifics in NHL: epcoritamab and glofitamab

Krish Patel • 16 Jun 2022
EHA 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Epcoritamab Glofitamab
EPCORE NHL-1

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, shares some insights into the promise of bispecific antibodies for the treatment of non-Hodgkin lymphoma, drawing focus on the promising results obtained with the use of epcoritamab and glofitamab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Krish Patel

1:01
The current landscape of antibody-based therapies in R/R DLBCL
Krish Patel • 11 Dec 2023
1:31
Clinical outcomes are poor for CLL patients treated with venetoclax post-BTKi exposure
Krish Patel • 11 Dec 2023
1:25
Hypertension prevalence in CLL and how it is affected by acalabrutinib treatment
Krish Patel • 11 Dec 2023
1:06
Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel • 11 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals